Company profile
Elevation Oncology company profile
Elevation Oncology makes genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. Its lead candidate, seribantumab, which inhibits tumor growth driven by NRG1 fusions, is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion.
Business identity
- Contact email
- [email protected]
- Phone number
- (716) 371-1125
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 11-50 employees
- Founded
- 2019-01-01, Year
Headquarters
- Headquarters
- Troy, New Hampshire, United States
- Postal code
- 10106
- Country code
- US
- Continent
- North America